Zacks Research Predicts Masimo’s Q1 Earnings (NASDAQ:MASI)

Masimo Co. (NASDAQ:MASI) – Equities research analysts at Zacks Research issued their Q1 2025 earnings estimates for shares of Masimo in a research report issued to clients and investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay forecasts that the medical equipment provider will earn $1.25 per share for the quarter. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.47 EPS, FY2025 earnings at $5.32 EPS, Q1 2026 earnings at $1.41 EPS, Q2 2026 earnings at $1.45 EPS, Q3 2026 earnings at $1.44 EPS, Q4 2026 earnings at $1.60 EPS and FY2026 earnings at $5.90 EPS.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million.

Several other analysts have also recently issued reports on the stock. Piper Sandler upped their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Wells Fargo & Company upped their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Finally, Raymond James upped their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Stock Down 2.2 %

Shares of NASDAQ MASI opened at $165.82 on Friday. Masimo has a 12-month low of $101.61 and a 12-month high of $194.88. The stock has a market cap of $8.95 billion, a PE ratio of 114.36 and a beta of 1.04. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average of $174.99 and a 200 day moving average of $159.19.

Hedge Funds Weigh In On Masimo

Hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp purchased a new position in shares of Masimo during the 4th quarter worth approximately $27,000. UMB Bank n.a. boosted its position in shares of Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares during the period. Trust Co. of Vermont purchased a new position in shares of Masimo during the 4th quarter worth approximately $33,000. Blue Trust Inc. boosted its position in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 64 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Insider Activity

In other news, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This represents a 55.38 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.70% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.